Table 3 Current clinical trials using CAR T cells for immunotherapy of AML
From: Recent developments in immunotherapy of acute myeloid leukemia
Study identifier | Study name | Target | Designation | Generation | Costim. domain | Transduction method | Median dosage | Conditioning chemotherapy | Clinical phase | Indication | Primary endpoints | (Estimated) Enrollment | Sponsor | Country | Study start | (Estimated) Completion date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT01864902 | Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33 (CART33) | CD33 | CART-33 | 2nd | 4-1BB | Lentiviral | 4.26 × 108 CAR T cells | n.a. | I/II | r/r AML or AML in CR2 or later if not a candidate for allo-HSCT; CD33 expression | Toxicity | 10 (1 patient reported) | Chinese PLA General Hospital | China | 2013 | 2017 | Recruiting |
NCT02159495 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | CD123 | CD123R(EQ) 28Z/EGFRt | 2nd | CD28 | Lentiviral | Variable | Cyclophosphamide +/− fludarabine +/− etoposide | I | r/r AML | DLT, toxicity | 30 | City of Hope Medical Center | USA | 2015 | 2017 | Recruiting |
NCT02203825 | Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | NKG2D-ligands | CM-CS1 T-cells | 2nd | DAP10 | Retroviral | 1 × 106 − 3 × 109 CAR T cells/kg | n.a. | I | r/r MDS-RAEB, r/r AML, r/r MM | Toxicity, feasibility | 12 | Celyad | USA | 2015 | 2017 | Active, not recruiting |
NCT03190278 | Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia (AML123) | CD123 | UCART123 | n.a. | n.a. | n.a. | 6.25 × 105 − 6.25 × 106 CAR T cells/kg | n.a. | I | r/r AML | Safety, efficacy | 156 | Cellectis S.A. | USA | 2017 | 2021 | Recruiting |